MEDPACE HOLDINGS INC•Financial Summary•AI-Powered Insights

MEDPACE HOLDINGS INC 2026 Q1
Earnings Overview & AI Insights

Detailed performance report for MEDPACE HOLDINGS INC covering Q1 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

MEDPACE HOLDINGS INC (2026 Q1)

Earnings Performance

No Performance Data

Summary of Financial Performance: Medpace reported strong Q1 2026 results with revenue of $706.6 million, up 26.5% year over year, and EBITDA of $149.4 million, up 25.9%. EBITDA margin was 21.1%, essentially flat with last year, as higher reimbursable costs were offset by lower employee-related costs. Net income rose 8.1% to $123.9 million, and diluted EPS increased to $4.28 from $3.67. Operating cash flow was $151.8 million, with negative 58.8 days sales outstanding and $652.7 million in cash. Backlog ended at about $2.9 billion, up 2.9% year over year, with ~$1.94 billion expected to convert over the next 12 months.

Company Outlook & Strategy: Management left 2026 guidance unchanged for revenue, EBITDA, net income, and EPS, assuming a 19%–20% tax rate and $27.5 million of interest income. The company emphasized improving win rates and expanding its opportunity pipeline as key priorities, while noting it cannot control cancellation rates. Management sounded cautiously constructive on demand quality, citing strong initial award notifications and win rates despite lower sequential RFP activity.

Key Industry Trends: RFP volumes were down sequentially and year over year, while cancellations across the industry/portfolio remained elevated relative to historical norms. Management said cancellation activity was driven by typical project-specific issues rather than macro/financial stress. Cancellations were concentrated mainly in oncology and cardiovascular, consistent with Medpace’s usual mix.

Operational Highlights: Net new business awards entering backlog increased 23.7% year over year to $618.4 million, producing a net book-to-bill of 0.88. Backlog conversion in Q1 was 23.3% of beginning backlog. Margin performance remained stable despite mix-related cost pressure. Management also noted this was Jesse Geiger’s final earnings call after 18.5 years at the company.

Challenges & Risks: The main near-term challenge is elevated cancellations, which reached their highest level in over a year and pressured book-to-bill. Management said these were mostly random/project-specific items such as product performance and reprioritization, not acute funding issues. Lower RFP volumes also create some headwind to near-term growth visibility. Customer concentration remains notable, with the top five customers representing about 28% of last-12-months revenue.

Key Analyst Questions & Responses: Analysts focused primarily on cancellation trends, causes, and whether they were also affecting the initial-award pipeline. Management said Q1 cancellations were mostly backlog-related, not significantly elevated in the initial-award bucket, and were not driven by macro stress. They declined to quantify pipeline size or the “initial awards” bucket, but said the higher cancellation period has reduced revenue opportunities and that a normalization in cancellations would support more regular conversion into backlog and revenue.

Earnings Call Transcript

Access the official earnings call transcript for MEDPACE-HOLDINGS-INC 2026 Q1. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.